Review of nemonoxacin with special focus on clinical development

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 765-774

  Qin, Xiaohua ^a   Huang, Haihui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Clinical development; Community acquired pneumonia; Nemonoxacin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; DAPTOMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NEMONOXACIN; PSEUDOMONIC ACID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; QUINOLONE DERIVATIVE;

ADVERSE OUTCOME; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL STUDY; COMMUNITY ACQUIRED PNEUMONIA; CONTACT DERMATITIS; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERANCE; ERYTHEMA; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PRURITUS; RASH; REVIEW; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTHEMIA; URINARY TRACT INFECTION; ANIMAL; CLINICAL TRIAL (TOPIC); COMMUNITY-ACQUIRED INFECTIONS; PNEUMONIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; QUINOLONES;

EID: 84904053736     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S63581     Document Type: Review

References (31)

1. Rice LB. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc. 2012;2(87):198-208.
2. Karpiuk I, Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl Epidemiol. 2013;67(3):455-460, 557-561. Polish [with English abstract].
3. Arjona A. Nemonoxacin Quinolone antibiotic. Drugs Future. 2009; 3(34):196-203.
4. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4915-4920.
5. Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother. 2009;64(6):1226-1229.
6. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010;54(3):1338-1342.
7. Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfuorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58(3):1800-1801.
8. Chen YH, Liu CY, Ko WC, et al. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. Eur J Clin Microbiol Infect Dis. 2014;33(2):233-239.
9. Hsu MS, Liao CH, Liu CY, Yang CJ, Huang YT, Hsueh PR. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents. Int J Antimicrob Agents. 2011;37(3):276-278.
10. Chung K P, Tseng S P, Huang YT, Tsai TH, Teng LJ, Hsueh PR. Arrival of Klebsiella pneumoniae carbapenemase (KPC)-2 in Taiwan. J Antimicrob Chemother. 2011;66(5):1182-1184.
11. Yang JC, Lee PI, Hsueh PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis. 2010;29(11):1369-1375.
12. Liao CH, Ko WC, Lu JJ, Hsueh PR. Characterizations of clinical isolates of clostridium diffcile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fdaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother. 2012;56(7):3943-3949.
13. Lin YC, Huang YT, Tsai PJ, et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium diffcile in Taiwan. Antimicrob Agents Chemother. 2011;55(4):1701-1705.
14. Lai CC, Tan CK, Lin SH, et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother. 2009;64(1):73-78.
15. Lai CC, Liu WL, Ko WC, et al. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species. Antimicrob Agents Chemother. 2011;55(5):2084-2091.
16. Tan CK, Lai CC, Liao CH, et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifoxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2009;64(2):428-429.
17. King CHR, Lin L, Leunk R. In vitro resistance development to nem-onoxacin for Streptococcus pneumoniae. In: Program and abstracts of 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC. Abstract C1-1971.
18. Li CR, Li Y, Li GQ, et al. In vivo antibacterial activity of nemonoxacin, a novel non-fuorinated quinolone. J Antimicrob Chemother. 2010; 65(11):2411-2415.
19. Hsu CH, Lin L, Leunk R, et al. In vivo efficacy of nemonoxacin in a mouse protection model. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2008;54-54.
20. Hsu CH, Lin L, Leunk R, et al. In vivo efficacy of nemon-oxacin in a mouse pulmonary infection model. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2008:43.
21. Lin L, Chang LW, Tsai CY, et al. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):405-410.
22. Guo B, Zhang J, Yu J, Wu X, Shi Y, Tsai CY. A liquid chroma-tography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharma-cokinetic study in healthy Chinese volunteers. Biomed Chromatogr. 2012;26(11):1333-1340.
23. Guo B, Wu X, Zhang Y, et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig. 2012;32(7):475-486.
24. Chung DT, Tsai CY, Chen SJ, et al. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):411-417.
25. Chow C P, Tsai C Y, Yeh CF, et al. In vitro metabolism and interaction of nemonoxacin (TG-873870) on human hepatic CYP3A4. In: Abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract A-27.
26. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fuoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46(5):669-683.
27. Liang W, Chen YC, Cao YR, et al. Pharmacokinetics and pharmaco-dynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 2013;57(7): 2942-2947.
28. Bochud PY, Moser F, Erard P, et al. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore). 2001;80(2): 75-87.
29. Falguera M, Sacristán O, Nogués A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med. 2001;161(15):1866-1872.
30. van Rensburg DJ, Perng R P, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofoxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54(10):4098-4106.
31. Kosinski MA, Lipsky BA. Current medical management of diabetic foot infections. Expert Rev Anti Infect Ther. 2010;8(11):1293-1305.